Multi-center randomized phase ii study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma

HIGHLIGHTS

• who: Nicholas Brown and colleagues from the Institute of Health Research/Wellcome University Institute, University College London, London, United Kingdom have published the paper: Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma, in the Journal: PLOS ONE | DOI:10.1371/journal.pone [0156369]. May 27, 2016 of /1371/
• what: In this investigational study the authors propose the use of a combination of therapies targeting the VEGF (cediranib) and EGFR (gefitinib) pathways in patients with recurrent glioblastoma, a group of patients with a clearly . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.